Skip to content
Aperlena
Free alerts

Germany - Medicines - Discount agreement under section 130a paragraph 8 SGB V in conjunction with section 130c paragraph 1 SGB V for the medicines Alprolix (B02BD04), Elocta (B02BD02) and Altuvoct (B02BD02) for the treatment of haemophilia

Original Deutschland - Arzneimittel - Arzneimittelrabattvertrag nach § 130a Abs. 8 SGB V i.V.m. § 130c Abs. 1 SGB V zu den Arzneimitteln Alprolix (B02BD04), Elocta (B02BD02) und Altuvoct (B02BD02) zur Behandlung der Hämophilie

Awarded Contract award

Key facts

Winner
Swedish Orphan Biovitrum GmbH
Buyer
AOK Sachsen - Anhalt
Where
Germany
Procedure
Negotiated procedure The buyer selects candidates, then negotiates the offers before choosing. Full entry Above the EU threshold A contract large enough that EU-wide rules apply and it must be published on TED. Full entry
CPV code The EU's common vocabulary for what is being bought: an eight-digit code every notice carries. Full entry
33600000 Pharmaceutical products
Original language
German
Source
via TED - Tenders Electronic Daily (Publications Office of the EU), verified 2 weeks ago
Notice number
608423-2026
Watch this tender

Bidding is closed. An award or a correction on this notice: an email when the register sees it. Log in

  1. Published
  2. Awarded pending

Summary

Machine-generated summary

AOK Sachsen-Anhalt has concluded a discount agreement under section 130a paragraph 8 SGB V in conjunction with section 130c paragraph 1 SGB V with the manufacturer of the medicines Alprolix (B02BD04), Elocta (B02BD02) and Altuvoct (B02BD02), used to treat haemophilia. The contract was awarded to Swedish Orphan Biovitrum GmbH and takes effect on 01.09.2026. The agreement sets discounts for these finished medicinal products of the contractor that are billed at the expense of the contracting party during the contract term on the applicable prescription form, such as Muster 16, Muster e16A or the digital forms of the BMV-AE agreement.

Description

Die AOK Sachsen-Anhalt hat zur Behandlung der Hämophilie mit dem Hersteller der Arzneimittel Alprolix (B02BD04), Elocta (B02BD02) und Altuvoct (B02BD02) zum 01.09.2026 einen Vertrag gem. § 130a Abs. 8 SGB V i.V.m. § 130c Abs. 1 SGB V abgeschlossen. Gegenstand dieses Vertrages ist die Vereinbarung von Rabatten gemäß § 130a Abs. 8 SGB V i.V.m. § 130c Abs. 1 SGB V für die Fertigarzneimittel Alprolix (B02BD04), Elocta (B02BD02) und Altuvoct (B02BD02) des Auftragnehmers, die während der Vertragslaufzeit zu Lasten der Auftraggeberin auf dem jeweils gültigen Arzneiverordnungsblatt ( z.B. Muster 16 oder Muster e16A der Vordruckvereinbarung bzw. der Vordruckvereinbarung digitale Vordrucke zum BMV-Ä) abgerechnet werden.

Official source

Source: TED - Tenders Electronic Daily (Publications Office of the EU)

Always verify details on the official notice.

Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 2 weeks ago

View the official notice

More from this buyer

Full buyer profile

56 open tenders right now

Recent awards

Similar tenders

Market context

Avg. open tender · Medical equipment & pharmaceuticals
€11,266,127
9,617 open across Europe right now
Buyer track record on Aperlena
93 notices tracked · 36 awarded
€2,700,013 in awarded contracts

Never miss a tender like this

58 new notices in Medical equipment & pharmaceuticals in Germany in the last 7 days. Get an email when new ones appear. Free.

Set up my alert
Open notice

Keyboard shortcuts

Read a list without reaching for the mouse. The shortcuts stay quiet while you type in a field.

j
Next result
k
Previous result
Enter
Open the result
n
Next page
p
Previous page
c
Compare this result
s
Shortlist this result
/
Search from any page
Ctrl K
Search from any page
?
Show these shortcuts
Esc
Close

Start from a question

Browse by sector

Index

Close
Log in

Language